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INTRODUCTION
Hepatitis B virus e antigen (HBeAg) negative chronic hep-
atitis B (CHB) represents a late phase of chronic hepatitis B
virus (HBV) infection usually caused by precore or basic core
promoter mutant viruses that are unable to produce HBeAg
(1). HBeAg negative CHB is predominantly found in the
Mediterranean region and Southern Europe, the middle East,
and Asian countries, including Korea (2, 3). The prevalence
of precore mutants varies geographically and is affected by the
HBV genotype. In North Europe and North America, where
genotype A predominates, HBeAg negative CHB is rare be-
cause cytosine at position 1858 (C-1858) precludes the selec-
tion of G1896A precore mutation. In Korea almost all pat-
ients with CHB have genotype C and both precore mutant
and basic core promoter mutant are very common (3-5).
HBeAg negative CHB is a potentially severe and progres-
sive form of liver disease with rare spontaneous remission and
a high risk of progression to liver cirrhosis (6, 7). Moreover,
it is harder to induce long-term sustained responsiveness after
antiviral therapy in HBeAg negative CHB patients. A sus-
tained-off therapy response rate has been reported at 10-30%
in response to conventional interferon-atherapy (2, 8). There-
fore, oral nucleos(t)ide analogues have been primarily consid-
ered, and used as, a therapeutic for HBeAg negative CHB. 
Lamivudine is the first oral nucleoside analogue that has
been used in the treatment of patients with HBeAg negative
CHB. Therapy for 1 yr achieves complete (both biochemical
and virological) responses at the end of therapy in approxima-
tely 2/3 of the patients (9-13). However, relapse after with-
drawal of lamivudine is universal in patients who were treat-
ed for only 1 yr (14). Long-term maintenance therapy with
lamivudine has been tried, but the response rate decreases
with time because of the increasing emergence of lamivudine
resistant mutants (9, 11, 12, 15). Most hepatitis B guidelines
suggest that HBeAg negative CHB should be treated with
oral nucleos(t)ide analogues for more than 1 yr, yet fail to ad-
dress the duration of oral nucleos(t)ide analogues therapy be-
yond the first year (16-18). American Association for the Study
of Liver Disease (AASLD) guideline suggest that treatment
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Clinical Efficacy of a 24-months Course of Lamivudine Therapy 
in Patients with HBeAg Negative Chronic Hepatitis B: A Long-term
Prospective Study 
The optimal duration of oral nucleos(t)ide analogue therapy for HBeAg negative chr-
onic hepatitis B (CHB) has not been defined. The aim of this study was to investi-
gate the clinical efficacy of  24-months course of lamivudine therapy in patients with
HBeAg negative CHB in Korea. A total of 50 Korean patients with HBeAg negative
CHB were prospectively enrolled. The patients received 100 mg/day of lamivudine
orally for 24 months. Patients who showed complete response at 24 months to lam-
ivudine therapy stopped treatment, and regular follow-up was done thereafter. The
mean follow-up duration after cessation of therapy was 40.8±22.7 (range 12-96)
months. The complete response rate at months 12 and 24 were 86.0% (43/50) and
86.0% (43/50), respectively, and the clinical breakthrough at months 12 and 24 were
4.0% (2/50) and 14.0% (7/50), respectively. The expected durability of responses at
months 12, 24, and 36 after cessation of lamivudine therapy in 43 complete respon-
ders was 79.1%, 64.0%, and 56.9%, respectively. In conclusion, a 24-months co-
urse of lamivudine therapy shows high end-treatment response rate and substan-
tial durability of initial response after cessation of therapy in HBeAg negative CHB
patients in Korea. 
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should be continued until the patient has achieved HBsAg
clearance (16). However, long-term nucleos(t)ide analogue
therapy has the potential risk of developing resistance or drug
toxicity. In this study, we prospectively investigated the clin-
ical efficacy of a 24-months course of lamivudine therapy in
patients with HBeAg negative CHB.
MATERIALS AND METHODS
Patients and design of study 
This prospective study included a total of 50 patients with
HBeAg negative CHB who started lamivudine therapy be-
tween December 1997 and December 2004 at Gangnam
Severance Hospital in Korea. Over the course of 24 months,
100 mg of lamivudine was administered to patients daily.
Patients who showed complete response at 24 months were
removed from lamivudine therapy and had regular follow-up.
Lamivudine therapy continued in patients who did not show
complete response at 24 months. Patient followed-up con-
sisted of physical examination, a routine laboratory test at
least every 3 months, and an HBV DNA test at least every
6 months to check for any breakthrough. Complete response
was defined as both normalization of alanine aminotransferase
(ALT) and undetectability of HBV DNA (<0.5 pg/mL)
according to hybrid capture assay.
Inclusion criteria was as follows: 1) Hepatitis B surface anti-
gen (HBsAg) positive and HBeAg negative for longer than
6 months; 2) ALT elevation >1.5 of the upper limit of normal
levels and HBV DNA positive within one month of the stu-
dy; 3) No history of previous antiviral therapy; and 4) No in-
terferon-atreatment within 18 months before the enrollment.
No patients were positive to anti-hepatitis C virus (HCV)
antibody (Ab) or anti-human immunodeficiency virus (HIV)
Ab. Patients who had decompensated liver disease or hepato-
cellular carcinoma were excluded. This study was approved
by the institutional review board (IRB approval number: 3-
2007-0060) at Gangnam Severance Hospital (Seoul, Korea),
and all participants gave written, informed consent. 
HBV serological markers
HBsAg and HBeAg/Ab were determined by enzyme im-
munoassay (Dade Behring, Marburg, Germany). HBV DNA
was measured by Digene hybrid capture assay (Digene Diag-
nostics, Beltsville, MD, USA) with a lower limit of 0.5 pg/mL.
The antibody against HCV was detected by a third-genera-
tion enzyme-linked immunosorbent assay (Korea Greencross,
Yongin, Korea). 
Statistics
All data were analyzed using the statistical software SPSS
(version 11.0, SPSS Inc., Chicago, IL, USA). Quantitative
variables are expressed as mean±standard deviation. Data
were analyzed using Student’s t-test, Mann-Whitney U test,
and the chi-square test. The Kaplan-Meier method was used
to estimate the durability of response after stopping lamivu-
dine therapy. Data were considered to be statistically signif-
icant with P<0.05.  
RESULTS
Baseline characteristics
The baseline characteristics of the 50 patients are presented
in Table 1. There were 39 men and 11 women, with a mean
age of 43±11 yr. Median serum AST and ALT levels were
152 IU/L and 239 IU/L, respectively. All patients were HBV
DNA positive (>0.5 pg/mL). Fifteen patients (30%) were clin-
ically diagnosed with liver cirrhosis. Twelve patients (24%)
had a history of previous interferon-a therapy. Thirty six pat-
ients (72%) had a family history of HBV infection. The total
follow-up duration from the beginning of lamivudine ther-
apy was 64.7±22.5 (range, 36-120) months.
Response and clinical breakthrough during a 24 months-
course of lamivudine therapy 
Complete response was defined as having both ALT nor-
malization and HBV DNA undetectability (<0.5 pg/mL) as
measured by the hybrid capture assay. The complete response
rate at 3, 6, 12, and 24 months of lamivudine therapy was
64.0% (32 of 50 patients), 90.0% (45 of 50), 86.0% (43 of
50), and 86.0% (43 of 50), respectively (Fig. 1). Cumulative
clinical breakthrough (HBV DNA positive conversion with
ALT re-elevation) occurred in 4.0% (2 of 50 patients) at 12
months, and 14.0% (7 of 50 patients) at 24 months of therapy
(Fig. 1). Lamivudine therapy was stopped in 43 patients who
showed complete response at the end of 24 months. Among
the 7 patients who did not show complete response at the end
of 24 months, 2 patients continued lamivudine therapy and
the other 5 patients switched to adefovir therapy. 
Patient characteristic Study population (n=50)
Sex, males (%) 39 (78.0%)
Age (yr), mean±SD (range) 43±11 (25-78)
AST (IU/L), median (range) 152 (37-587)
ALT (IU/L), median (range) 239 (80-548)
Patients with positive HBV DNA, n (%) 50 (100%) 
Liver cirrhosis, n (%) 15 (30.0%)
History of interferon treatment, n (%) 12 (24.0%)
Presence of family history of HBV infection, n (%) 36 (72.0%)
Total follow-up duration (months),  64.7±22.5 (36-120)
mean±SD (range)
Table 1. Baseline characteristics of patients884 Y.H. Paik, J.K. Kim, D.Y. Kim, et al.
Durability of response after cessation of lamivudine therapy
The 43 patients who showed complete response without
evidence of clinical breakthrough at 24 months of lamivudine
therapy were removed from treatment and regular follow-up
was done thereafter. In these patients, the mean duration of
follow-up after cessation of lamivudine therapy was 40.8±
22.7 (range 12-96) months. The number of patients at fol-
low up months 12, 24, 36, 48, and 60 were 33, 18, 14, 8,
and 5, respectively. The expected durability of response after
cessation of 24 months-course lamivudine therapy was calcu-
lated by the Kaplan-Meier method, and the results at months
12, 24, 36, 48, and 60 of follow-up were 79.1%, 64.0%,
56.9%, 47.4%, and 47.4%, respectively (Fig. 2). There were
no episodes of hepatic decompensation in relapsed patients
after withdrawal of lamivudine. When comparing the char-
acteristics of those who have relapsed and those who have not
relapsed, the proportion of liver cirrhosis patients was signif-
icantly higher in relapsers than non-relapsers (44% vs. 16%,
P=0.040). Meanwhile, there was no difference in age, sex,
baseline ALT level, previous interferon treatment history,
family history of hepatitis B, or the follow-up duration after
cessation of lamivudine therapy between the two groups
(Table 2). 
Response during lamivudine re-treatment in relapsed
patients after cessation of lamivudine therapy 
Fourteen patients among 18 patients who relapsed after ces-
sation of lamivudine therapy were retreated with lamivudine.
Complete response rates at 3, 6, 12, 18, and 24 months of
lamivudine re-treatment were 64.2% (9 of 14 patients), 92.8%
(13 of 14 patients), 100.0% (14 of 14 patients), 83.3% (10
of 12 patients), 70.0% (7 of 10 patients), respectively (Fig. 3).
Clinical breakthrough (HBV DNA positive conversion with
ALT re-elevation) occurred in 30.0% of patients during the
second year of the re-treatment period (Fig. 3). The flow chart
of the 24-months course of lamivudine therapy in HBeAg
negative CHB patients is illustrated in Fig. 4. 
DISCUSSION
Lamivudine has been widely used as an initial antiviral
agent for the treatment of patients with chronic hepatitis B.
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Fig. 1. Complete response rate (hatched bar) and breakthrough
rate (black bar) during a 24 months-course of lamivudine therapy
in HBeAg negative CHB patients. Complete response was defined
as having both ALT normalization and HBV DNA undetectability
(<0.5 pg/mL) as measured by the hybrid capture assay. Clinical
breakthrough was defined as HBV DNA positive conversion with
ALT re-elevation.
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Complete response Breakthrough
90.0
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*P<0.05 
CH, chronic hepatitis; LC, liver cirrhosis.
Non-relapsers
(n=25)
Parameters
Relapsers
(n=18)
P value
Age (yr) 41.5±10.7 44.0±13.8 0.528
Sex (M:F) 18:7 14:4 0.736
CH:LC 21:4 10:8 0.040*
AST, pretreatment (IU/L) 172.3±95.8 179.7±122.0 0.832
ALT, pretreatment (IU/L) 272.9±128.3 265.7±86.1 0.837
ALT subgroup (ULN)   1/9/15 0/5/13 0.555
<2/2-5/≥5
Interferon treatment history  4:21 5:13 0.455
(yes:no)
Family history of HBV infection  17:8 14:4 0.731
(yes:no)
F/U duration after cessation  37.9±24.3 44.8±20.1 0.315
of lamivudine
Table 2. Comparison of characteristics between relapsers and
nonrelapsers after cessation of 24 months-course lamivudine
therapy
Fig. 2. Expected durability of response after cessation of lamivu-
dine in 43 patients who showed complete response at 24 months
of lamivudine therapy (Kaplan Meier analysis). Durability of respon-
se rates at 1, 2, and 3 yr are 79.1%, 64.0%, and 56.9%, respec-
tively. 
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Although there have been recent developments of anti-viral
agents with a lower probability of viral resistance, such as ade-
fovir or entecavir, lamivudine is still being widely used due
to relatively cheap cost, rapid action, and proven safety for
long-term use. Lamivudine monotherapy has been shown to
benefit patients with HBeAg positive- or HBeAg negative-
CHB (12, 19). For HBeAg positive CHB, HBeAg loss or
seroconversion has been used as an indicator for considering
when to stop oral antiviral therapy (16-18). According to
AASLD practice guidelines, lamivudine therapy should be
continued at least 6 months after the achievement of HBeAg
seroconversion (16). 
However, there is no indicator to determine treatment dura-
tion in HBeAg negative CHB patients. The optimal duration
of treatment in HBeAg negative CHB is unknown. One year
treatment with lamivudine in HBeAg negative CHB patients
resulted in HBV DNA suppression to undetectable levels by
PCR in 60 to 70% of patients (9-13). Most patients relapsed
after withdrawal of lamivudine after 1 yr of treatment (14).
This result supports the rationale that most practice guide-
lines recommend prolonged oral nucleos(t)ide analogue treat-
ment for a period exceeding 1 yr in patients with HBeAg neg-
ative CHB (16-18). 
Several prolonged antiviral therapies, for periods longer than
1 yr, have been tried in HBeAg negative CHB patients. Viro-
logical and biochemical response rates peaked at 12 months
and decreased thereafter (9-13). It was reported that virolog-
ical remission rates at years 1, 2, and 3 were 77%, 52%, and
42%, respectively, in Greek patients with HBeAg negative
CHB. HBV genotype D is predominant in Greece, and al-
most all patients had HBV with precore stop codon mutation
(11). Another study conducted in Greece reported that the
virological response rate during the second year of lamivudine
therapy in HBeAg negative patients was 34% (12). Long-term
therapy with lamivudine in HBeAg negative CHB patients
in the Mediterranean region, has been associated with increas-
ing rates of virological breakthrough due to the selection of
mutants of the YMDD motif of HBV DNA polymerase gene
(rtM204I/V±rtL180M) (9, 11, 12, 15). Therefore, the dec-
ision to continue oral nucleos(t)ide therapy beyond 1 yr in
HBeAg negative CHB should weigh the likelihood of benefit
against the risk of developing resistance or drug toxicity (17).
There are two intriguing reports that confine the duration
of antiviral therapy to two years in HBeAg negative CHB
patients (20, 21). A study with a limited number of patients
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Fig. 3. Complete response during re-treatment in patients who re-
lapsed after stopping lamivudine therapy. Complete response rate
at 12 and 24 months of re-treatment was 100% and 70.0%, respec-
tively. 
64.2%
(9/14)
92.8%
(13/14)
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Fig. 4. A flow chart of a 24-months course of lamivudine therapy in HBeAg negative CHB patients. ETR, end of treatment response.
Total 50 patients
Lamivudine 100 mg/d
Response: 43 (86.0%) ETR at 2 yr Breakthrough: 7 (14.0)
Relapse: 18 (41.9%) No relapse: 25 (58.1%) Follow-up
(40.8±22.7 months)
Lamivudine: 2
Adeforvir: 5
Lamivudine
re-treatment: 14
1 yr response: 100% (8/8)
2 yr response: 70% (7/10)886 Y.H. Paik, J.K. Kim, D.Y. Kim, et al.
conducted in Spain, in which most patients had genotype A
or D, showed that the response rates at years 1 and 2 of lim-
ivudine therapy were 81% and 69% respectively (20). Anoth-
er study conducted in Canada reported that HBV DNA unde-
tectability rates at years 1 and 2 of treatment were 92% and
86%, respectively, according to the hybrid capture assay dur-
ing the 2-yr course of lamivudine therapy in 50 Chinese pati-
ents with HBeAg negative CHB. Most patients in the study
had the HBV genotype C (21). The expected durability rates
of virological response at 6, 12, and 18 months were 70%,
50%, and 50%, respectively (21). 
Our results showed that the initial response rate at years
1 and 2 of lamivudine therapy was 86.0% and 86.0%, respec-
tively, which compare well with those of a previous study by
Fung et al. (21). Unlike previous reports in the Mediterranean
region that show initial response rates during the first year
of therapy dramatically fall during the second year, our study
indicated that the initial response rate of the first year nearly
maintained until the end of the second year of lamivudine
treatment in Korean patients. Furthermore, our data indicat-
ed that the emergence rates of clinical breakthrough due to
viral resistance during years 1 and 2 of lamivudine therapy
were 4.0% and 14.0%, respectively, a rate lower than those
reported in Southern Europe (9, 11, 12, 15). Lok et al. (22)
reported that lamivudine resistant mutants were detected at
similar rates in both patients with HBeAg positive CHB and
those with HBeAg negative CHB. However, previous reports
conducted in Asia, including Hong Kong and Korea, report-
ed that the viral breakthrough rate was lower in HBeAg neg-
ative CHB patients than HBeAg positive CHB patients dur-
ing long-term lamivudine therapy (23-25). 
The differences of virological factors, including HBV geno-
type and the prevalence of precore or core promoter mutations,
between Southern Europeans and Koreans may contribute to
a difference in responsiveness to anti-viral therapy in HBeAg
negative CHB. Although we did not analyze HBV genotypes
or precore/core promoter mutations in this study, previous
reports demonstrate that almost all Korean patients with chro-
nic hepatitis B have genotype C and both precore mutant and
basic core promoter mutants are very common in HBeAg
negative CHB patients in Korea (3-5). Lamivudine therapy
resulted in transient reversion to wild-type HBV from pre-
core/core promoter mutants in Korea (26), but these changes
were not observed in a long-term study of Greek patients
treated with lamivudine (9). As the precore and core promot-
er mutants decrease or abolish HBeAg excretion and increase
replication capacity (27, 28), the transient reversion to wild
type precore/core promoter HBV, during lamivudine thera-
py in Korean HBeAg negative CHB patients, may delay the
emergence of lamivudine-resistant mutant HBV in Korea.
However, further studies will be needed to investigate the
mechanism of the low rate of lamivudine resistance in Kore-
an patients with HBeAg negative CHB. 
Our data showed that the expected off-treament durability
at months 12, 24, and 36 of follow-up in complete responders
after a 24-months course of lamivudine therapy was 79.1%,
64.0%, and 56.9%, respectively. Most patients who relapsed
after cessation of lamivudine therapy occurred within 24 mon-
ths and then reached a plateau after 48 months of withdrawal
from lamivudine therapy. Our data indicate that a 24-months
course of lamivudine therapy could induce long-term remis-
sion in approximately half of the patients with HBeAg neg-
ative CHB in Korea, suggesting a 24-months course of lam-
ivudine therapy could be a feasible option as a first line thera-
peutic strategy in the treatment of HBeAg negative CHB in
Korean patients. When we compared the characteristics of
relapsers and non-relapsers, the proportion of liver cirrhosis
was significantly higher in relapsers than non-relapsers, sug-
gesting cirrhotic patients with HBeAg negative CHB may
require prolonged treatment (16-18). Of the patients who
relapsed after withdrawal from lamivudine, none developed
hepatic decompensation. Those patients who relapsed after
withdrawal from lamivudine therapy were re-treated. Inter-
estingly, the patient response to re-treatment was substantial.
Nearly all patients showed ALT normalization with HBV
DNA undetectability at 1 yr after re-treatment with lami-
vudine. 
Our study had several limitations. The number of patients
included was relatively small, and HBV DNA was measured
by the hybrid capture assay, which is less sensitive than a PCR-
based assay. However, those limitations could not be over-
come in this study because the study was designed and start-
ed as a long-term prospective study from the late 1990s when
HBV DNA quantitation by PCR was not routinely used in
clinical setting. Based upon our data, a larger scaled study
adopting more sensitive HBV DNA quantitation method
would be necessary in the future.
In conclusion, A 24-months course of lamivudine therapy
in Korean patients shows a significant initial response rate, and
long-term remission can be maintained in about half of com-
plete responders at 24-months after withdrawal of lamivudine.
Moreover, lamivudine re-treatment is still effective in the viral
suppression in relapsers after cessation of lamivudine therapy.
Therefore a 24-months course of lamivudine therapy may be
a feasible option as a first line therapeutic strategy in the treat-
ment of HBeAg negative CHB in Korean patients. 
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